Amyloid-β Clearance Mechanisms in Alzheimer's Disease
The focus of this study is to examine the protein-plaque clearance (Aß) in relation to the blood-brain-barrier, the glymphatic system, brain lymphatic system and enzymatic degradation. In order to achieve this aim the investigators intend to study participants with a Subjective Cognitive Decline, Mild Cognitive Impairm
| Condition(s) | Alzheimer's Disease (AD) |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | The focus of this study is to examine the protein-plaque clearance (Aß) in relation to the blood-brain-barrier, the glymphatic system, brain lymphatic system and enzymatic degradation. In order to achieve this aim the investigators intend to study participants with a Subjective Cognitive Decline, Mild Cognitive Impairment and a mild Alzheimer's disease. |
| Who can participate | Inclusion Criteria: * Diagnosis of amnestic MCI or AD dementia or clinical normal * Able to provide written informed consent * Unchanged pharmacotherapy within 4 days prior to the study specific assessments * Fluent in German Exclusion Criteria: * Unable to give informed consent or has a legal guardian * Other severe mental disorder, e.g. schizophrenia or bipolar affective disorder * Clinically relevant depression * Acute suicidality * Current alcohol, drug or medication abuse * History of severe traumatic brain injury within 3 months prior to inclusion * Structural lesions of the basal ganglia or brain stem * Severe neurological disorder including (but not limited to) epilepsy, systemic disorders, stroke, repeated transient ischaemic attacks, increased brain intracranial pressure, normal |
| Ages | 50 Years to 85 Years |
| Sex | All |
| Lead sponsor | Ludwig-Maximilians - University of Munich |
| Locations | München, Bavaria, Germany |
| Start date | 2021-06-01 |
| NCT ID | NCT05059158 |
| Official listing | https://clinicaltrials.gov/study/NCT05059158 |